

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/835,537	04/16/2001	Carl R. Merril	PNC-004	5407
75	90 04/06/2006		EXAM	INER
M Elisa Lane			PRYOR, ALTON NATHANIEL	
Panacea Pharmaceuticals Inc 207 Perry Parkway			ART UNIT	PAPER NUMBER
Gaithersburg, MD 20877			1616	
			DATE MAILED: 04/06/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/835,537	MERRIL ET AL.				
Office Action Summary	Examiner	Art Unit				
•	Alton N. Pryor	1616				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period w Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE!	I. lely filed the mailing date of this communication. O (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 12/19)/06.					
	action is non-final.					
1 <u></u>	<u> </u>					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 19 and 21-35 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s)						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	election requirement.					
Application Papers						
9)☐ The specification is objected to by the Examine	r					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correct		• •				
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:		-(d) or (f).				
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau * See the attached detailed Office action for a list	, , , , ,	4				
See the attached detailed Office action for a list	or the certified copies not receive	u.				
Attachment(s)	_					
) Notice of References Cited (PTO-892)	4) Interview Summary					
Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te atent Application (PTO-152)				

Application/Control Number: 09/835,537 Page 2

Art Unit: 1616

DETAILED ACTION

I. Rejection of claims 19,21-35 under 35 USC 112, 1st paragraph will be maintained in light of amendment filed 12/19/05. Applicant argues: 1) Guanidinoacetate is not a salt and is not the same as guanidine acetate which is a salt; and 2)

Rejection does not provide a basis for limiting the claims to only named prion diseases. Examiner argues: Guanidinoacetate and guanidine acetate are equivalent compounds arising from a combination of guanidine and acetate; 2)

There exist basis for limiting Applicant to instant named prion diseases. Basis lie within what is disclosed in the specification, particularly working examples.

Claims are not in commensurate in scope with examples disclosed in the specification.

II. Rejection of claims 19,22-25,27-29 under 35 USC 102(e) as being anticipated and claim 30 under 35 USC 103(a) as being obvious over Kaddurah-Daouk will be maintained for reason on record and reasons as follows. Applicant argues: 1) Guanidinoacetate is not a salt and is not the same a guanidine acetate which is a salt (Applicant references USPN 5324731 for support). Examiner argues: Guanidinoacetate and guanidine acetate are equivalent compounds arising from a combination of guanidine and acetate.

Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 571-272-0621. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

Art Unit: 1616

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Examiner

AU 1616